

PUBLICATIONS – data from The Norwegian Renal Registry

(Author representing the registry is marked when T.Leivestad is not a co-author)

- 163: Kramer A, Pippias M, Stel V, . . . **Reisæter AV**, . . . Jager KJ, Noordzij M. Renal replacement therapy in Europe: a summary of the 2013 ERA-EDTA Registry Annual Report with a focus on diabetes mellitus
Clin Kidney J, 2016, 9: 457-469
- 162: Pippias M, Jager KJ, Kramer A, Leivestad T, Sánchez MB, Caskey FJ, Collart F, Couchoud C, Dekker FW, Finne P, Fouque D, Heaf JG, Hemmeler MH, Kramar R, Meester JD, Noordzij M, Palsson R, Pascual J, Zurriaga O, Wanner C, Stel VS. The changing trends and outcomes in renal replacement therapy: data from the ERA-EDTA Registry.
Nephrol. Dial. Transplant. 2016 31: 831-841
- 161: Eide IA, Dahle DO, Svensson M, Hartmann A, **Åsberg A**, Bjerve KS, Christensen JH, Schmidt EB, Lauritsen ME, Lund K, Jenssen T. Plasma levels of marine n-3 fatty acids and cardiovascular risk markers in renal transplant recipients.
Eur J Clin Nutr. 2016; 70: 824-830.
- 160: Ruggajo P, Skrunes R, Svarstad E, Skjærven R, **Reisæter AV**, Vikse BE. Familial Factors, Low Birth Weight, and Development of ESRD: A Nationwide Registry Study
Am J Kidney Dis. 2016; 67: 601-8
- 159: Pippias M, Stel VS, Aresté-Fosalba N, Couchoud C, Fernandez-Fresnedo G, Finne P, Heaf JG, Hoitsma A, De Meester J, Pálsson R, Ravani P, Segelmark M, Traynor JP, **Reisæter AV**, Caskey FJ, Jager KJ. Long-term Kidney Transplant Outcomes in Primary Glomerulonephritis: Analysis From the ERA-EDTA Registry.
Transplantation 2016;100:1955-62
- 158: Ruggajo P, Svarstad E, Leh S, Marti HP, **Reisæter AV**, Vikse BE. Low Birth Weight and Risk of Progression to End Stage Renal Disease in IgA Nephropathy--A Retrospective Registry-Based Cohort Study.
PloS ONE. 2016;11(4):e0153819.
- 157: Luitgaarden MWMvd, Jager KJ, Segelmark M, Pascua J, Collart F, Hemke AC, Remón C, Metcalfe W, Miguel A, Kramar R, **Aasarød K**, Hanna AA, Krediet RT, Schön S, Ravani P, Caskey FJ, Couchoud C, Palsson R, Wanner C, Finne P, Noordzij M. Trends in dialysis modality choice and related patient survival in the ERA-EDTA Registry over a 20-year period
Nephrol Dial Transplant 2016; 31: 120–128
- 156: Eide IA, Jenssen T, Hartmann A, Diep LN, Dahle DO, **Reisæter AV**, Bjerve KS, Christensen JH, Schmidt EB, Svensson M. Plasma levels of marine n-3 polyunsaturated fatty acids and renal allograft survival.
Nephrol Dial Transplant 2016; 31: 160–167
- 155: LindahlJP, Hartmann A, Aakhus S, Endresen K, Midtvedt K, Holdaas H, Leivestad T, Horneland R, Øyen O, Jenssen T. Long-term cardiovascular outcomes in type 1 diabetic

patients after simultaneous pancreas and kidney transplantation compared with living donor kidney transplantation

Diabetologia 2016; 59: 844-52.

154: Eide IA, Jenssen T, Hartmann A, Diep LN, Dahle DO, **Reisaeter AV**, Bjerve KS, Christensen JH, Schmidt EB, Svensson M. The association between marine n-3 polyunsaturated fatty acid levels and survival after renal transplantation.

Clin J Am Soc Nephrol 2015; 10: 1246-56

153: Smedbråten YV, Sagedal A, Mjøen G, **Hartmann A**, Fagerland M, Rollag H, Mollnes TE, Thiel S. High Ficolin-3 level at the time of transplantation is an independent risk factor for graft loss in kidney transplant recipients.

Transplantation 2015; 99: 791-796.

152: Hruskova Z, Stel VS, Jayne D, **Aasarød K**, De Meester J, Ekstrand A, Eller K, Heaf JG, Hoitsma A, Martos Jimenéz C, Ravani P, Wanner C, Tesar V, Jager KJ. Characteristics and Outcomes of Granulomatosis With Polyangiitis (Wegener) and Microscopic Polyangiitis Requiring Renal Replacement Therapy: Results From the European Renal Association-European Dialysis and Transplant Association Registry.

Am J Kidney Dis. 2015; 66: 613-20.

151: Knoop T, Vagane AM, **Vikse BE**, Svarstad E, Magnusdottir BT, Leh S, et al. Addition of eGFR and Age Improves the Prognostic Absolute Renal Risk-Model in 1,134 Norwegian Patients with IgA Nephropathy.

American Journal of Nephrology. 2015; 41: 210-9.

150: Morken NH; Diaz-Garcia C; Reisaeter AV; Foss A; Leivestad T; Geiran O; Hervas D; Brannstrom M. Obstetric and neonatal outcome of pregnancies fathered by males on immunosuppression after solid organ transplantation.

Am. J. Transpl. 2015; 15:1666-73.

149: Waldum-Grevbo B, Leivestad T, Reisaeter AV, Os I. Impact of initial dialysis modality on mortality: a propensity-matched study.

BMC Nephrology 2015; 16;179 – published online 30.Oct.2015

148: Breckenridge K, Bekker HL, Gibbons E, vd Veer SN, Abbott D, Briançon S, Cullen R, Garneata L, Jager KJ, **Lønning K**, Metcalfe W, Morton RL, Murtagh FEM, Prutz K, Robertson S, Rychlik I, Schon S, Sharp L, Speyer E, Tentori F, Caskey FJ. How to routinely collect data on patient-reported outcome and experience measures in renal registries in Europe: an expert consensus meeting

Nephrol Dial Transplant 2015; 30: 1605–1614

147: Dahle DO, Eide IA, Åsberg A, Leivestad T, Holdaas H, Jenssen TG, Fagerland MW, Pihlstrøm H, Mjøen G, Hartmann A. Aortic stiffness in a mortality risk calculator for kidney transplant recipients.

Transplantation 2015; 99: 1730-7.

- 146: Pippias M, Stel V, . . . Leivestad T, . . . Jager KJ. Renal replacement therapy in Europe: a summary of the 2012 ERA-EDTA Registry annual report.
Clin Kidney J 2015; 8: 248-261
- 145: Sandvik LF, Skarstein K, Krynitz B, Volchenkov R, Sviland L, Leivestad T, Jonsson R, Appel S. Peritumoral dermis of squamous cell carcinomas in renal transplant recipients contains less CD11c+ myeloid dendritic cells and FoxP3+ T cells compared to immunocompetent controls.
J Eur Acad Dermatol Venereol. 2015; 29:2128-35.
- 144: Sriskandarajah S, Aasarød K, Skrede S, Knoop T, **Reisæter AV**, Bjørneklett R. Improved prognosis in Norwegian patients with glomerulonephritis associated with anti-neutrophil cytoplasmic antibodies.
Nephrol Dial Transplant 2015; 30: i67–i75
- 143: Norum J, Leivestad T, Eriksen BO, Skår S, Fagerheim A, Reisæter AV. Regional differences in renal replacement therapy in northern Norway 2000-2012.
Int J Circumpolar Health 2015, 74:24298
- 142: Vogelzang JL, van Stralen KJ, Noordzij M, Abad Diez J, Carrero JJ, Couchoud C, Dekker FW, Finne P, Fouque D, Heaf JG, Hoitsma A, Leivestad T, de Meester J, Metcalfe W, Palsson R, Postorino M, Ravani P, Vanholder R, Wallner M, Wanner C, Groothoff JW, Jager KJ. Mortality from infections and malignancies in patients treated with renal replacement therapy: data from the ERA-EDTA registry
Nephrol Dial Transplant 2015; 30: 1028–1037
- 141: Skrunes R, Svarstad E, **Reisæter AV**, Vikse BE. Familial Clustering of ESRD in the Norwegian Population
Clin J Am Soc Nephrol 2014; 9, 1692-1700
- 140: von der Lippe N, Waldum B, Østhus TB, **Reisæter AV**, Os I. Health related quality of life in patients in dialysis after renal graft loss and effect of gender.
BMC Womens Health, 2014; 14: 34
- 141: Wühl E, van Stralen KJ, Wanner C, Ariceta G, Heaf JG, **Bjerre AK**, Palsson R, Duneau G, Hoitsma AJ, Ravani P, Schaefer F, Jager KJ. Renal replacement therapy for rare diseases affecting the kidney: an analysis of the ERA-EDTA Registry.
Nephrol Dial Transplant. 2014; 29 Suppl 4:iv1-iv8.
- 140: Chesnaye N, Bonthuis M, Schaefer F, Groothoff JW, Verrina E, Heaf JG, Jankauskiene A, Lukosiene V, Molchanova EA, Mota C, Peco-Antiæ A, Ratsch IM, **Bjerre A**, Roussinov DL, Sukalo A, Topaloglu R, Van Hoeck K, Zagozdzon I, Jager KJ, Van Stralen KJ; on behalf of the ESPN/ERA–EDTA registry. Demographics of paediatric renal replacement therapy in Europe: a report of the ESPN/ERA-EDTA registry.
Pediatr Nephrol. 2014 Jul 21

- 139: Noordzij M, Jager KJ, van der Veer SN, Kramar R, Collart F, Heaf JG, Stojceva-Taneva O, Leivestad T, Buturovic-Ponikvar J, Sánchez MB, Moreso F, Prütz KG, Severn A, Wanner C, Vanholder R, Ravani P. Use of vascular access for haemodialysis in Europe; a report from the ERA-EDTA registry.
Nephrol Dial Transplant 2014; 29: 1956-1964
- 138: Bleskestad IH, Bergrem H, Leivestad T, Hartmann A, Gøransson LG. Parathyroid hormone and clinical outcome in kidney transplant patients with optimal transplant function.
Clin Transplant 2014; 28: 479–486
- 137: Dahle DO, Jenssen T, Holdaas H, Leivestad T, Vårdal M, Mjøen G, Reisæter AV, Toft I, Hartmann A. Uric acid has a J-shaped association with cardiovascular and all-cause mortality in kidney transplant recipients.
Clin Transplant 2014; 28: 134–140
- 136: Lægreid IK, Aasarød K, Bye A, Leivestad T, Jordhøy M. The impact of nutritional status, physical function, comorbidity and early versus late start in dialysis on quality of life in older dialysis patients
Ren Fail 2014; 36 (1), 9-16
- 135: Smedbråten YV, Sagedal S, Leivestad T, Mjøen G, Osnes K, Rollag H, Reisæter AV, Foss A, Os I, Hartmann A. The impact of early cytomegalovirus infection after kidney transplantation on long-term graft and patient survival.
Clin Transplant 2014; 28: 120-6
- 134: Sandvik LF, Skarstein K, Sviland L, Svarstad E, Nilsen AE, Leivestad T, Jonsson R, Appel S. CD11c+ dendritic cells rather than Langerhans cells are reduced in normal skin of immunosuppressed renal transplant recipients.
Acta Derm Venereol. 2014;94:173-8
- 133: Harambat J, Bonthuis M, van Stralen KJ, Ariceta G, Battelino N, **Bjerre A**, Jahnukainen T, Leroy V, Reusz G, Sandes AR, Sinha MD, Groothoff JW, Combe C, Jager KJ, Verrina E, Schaefer F, for the ESPN/ERA-EDTA Registry. Adult Height in Patients with Advanced CKD Requiring Renal Replacement Therapy during Childhood.
Clin J Am Soc Nephrol 2014; 9: 92-9.
- 132: Noordzij M, Kramer A, . . . Leivestad T, . . . Jager KJ. Renal replacement therapy in Europe – a summary of the 2011 ERA-EDTA Registry annual report.
Clin Kidney J 2014; 7: 227-238
- 131: Mjøen G, Hallan S, Hartmann A, Foss A, Midtvedt K, Øyen O, Reisæter A, Pfeffer P, Jenssen T, Leivestad T, Line P-D, Øvrehus M, Dale DO, Pihlstrøm H, Holme I, Dekker FW, Holdaas H. Long-term risks for kidney donors
Kidney International 2014; 86:162-7

- 130: Andresen PA, Nymoen DA, Kjørheim K, Leivestad T, Helsing P. Susceptibility to cutaneous squamous cell carcinoma in renal transplant recipients associates with genes regulating melanogenesis independent of their role in pigmentation.
Biomarkers in Cancer 2013;5: 41-47
- 129 Schroijen MA, Luijngaarden MWMvd, Noordzij M, Ravani P, Jarraya F, Collart F, Prütz KG, Fogarty DG, Leivestad T, Prischl FC, Wanner C, Dekker FW, Jager KJ, Dekkers OM. Survival in dialysis patients is different between patients with diabetes as primary renal disease and patients with diabetes as a co-morbid condition.
Diabetologia. 2013;56:1949-57.
- 128: Dörje C, Midtvedt K, Holdaas H, Naper C, Strøm EH, Øyen O, Leivestad T, Aronsen T, Jenssen T, Flaa-Johnsen L, Lindahl JP, Hartmann A, Reisæter AV. Early versus late acute antibody-mediated rejection in renal transplant recipients.
Transplantation. 2013;96:79-84.
- 127: Knoop T, Vikse BE, Svarstad E, Leh S, **Reisæter AV**, Bjørneklett R. Mortality in patients with IgA nephropathy.
Am J Kidney Dis. 2013; 62: 883-90
- 126: Dahle DO, Midtvedt K, Hartmann A, Jenssen T, Holdaas H, Mjøen G, Leivestad T, Asberg A. Endothelial dysfunction is associated with graft loss in renal transplant recipients.
Transplantation. 2013;95:733-9
- 125: Heldal K, Thorarinsdottir S, Hartmann A, Leivestad T, Reisæter AV, Foss AE, Midtvedt K. Induction with interleukin-2 antagonist for transplantation of kidneys from older deceased donors: an observational study.
Transplant Res. 2013; 2:11.
- 124: Lindahl JP, Hartmann A, Horneland R, Holdaas H, Reisæter AV, Midtvedt K, Leivestad T, Øyen O, Jenssen T. Improved patient survival with simultaneous pancreas and kidney transplantation in recipients with diabetic end-stage renal disease.
Diabetologia 2013 56(6):1364-71.
- 123: Kramer A, Stel VS, . . . Leivestad T, . . . Jager KJ. Renal replacement therapy in Europe – a summary of the 2010 ERA-EDTA Registry annual report.
Clin Kidney J 2013;6:105-115
- 122: Åsberg A, Apeland T, Reisæter AV, Foss A, Leivestad T, Heldal K, Thorud LO, Eriksen BO, Hartmann A, on behalf of the NILS study group. Long-term outcomes after cyclosporine or mycophenolate withdrawal in kidney transplantation – results from an aborted trial.
Clin Transplant. 2013; 27(2): E151-6.
- 121: van Stralen KJ, Verrina E, Belingheri M, Dudley J, Dusek J, Grenda R, Macher MA, Puretic Z, Rubic J, Rudaitis S, Rudin C, Schaefer F, Jager KJ; ESPN/ERA-EDTA Registry.

(among named collaborators: Bjerre A, Leivestad T) Impact of graft loss among kidney diseases with a high risk of post-transplant recurrence in the paediatric population.

Nephrol Dial Transplant. 2013; 28(4):1031-8.

120: Vikse BE, Irgens LM, Karumanchi SA, Thadhani R, **Reisæter AV**, Skjærven R. Familial factors in the association between preeclampsia and later ESRD.

Clin J Am Soc Nephrol. 2012;7(11):1819-26.

119: van Stralen KJ, Krischock L, Schaefer F, Verrina E, Groothoff JW, Evans J, Heaf J, Ivanov D, Kostic M, Maringhini S, Podracká L, Printza N, Pundziene B, Reusz GS, Vondrak K, Jager KJ, Tizard EJ; ESPN/ERA-EDTA Registry. (among named collaborators: Leivestad T, Brackman D). Prevalence and predictors of the sub-target Hb level in children on dialysis.

Nephrol Dial Transplant. 2012 ;27(10):3950-7.

118: Temme J, Kramer A, Jager KJ, Lange K, Peters F, Müller GA, Kramar R, Heaf JG, Finne P, Palsson R, **Reisæter AV**, Hoitsma AJ, Metcalfe W, Postorino M, Zurriaga O, Santos JP, Ravani P, Jarraya F, Verrina E, Dekker FW, Gross O. Outcomes of male patients with Alport syndrome undergoing renal replacement therapy.

Clin J Am Soc Nephrol. 2012;7(12):1969-76

117: Kramer A, Stel VS, Geskus RB, Tizard EJ, Verrina E, Schaefer F, Heaf JG, Kramar R, Krischock L, Leivestad T, Palsson R, Ravani P, Jager KJ. The effect of timing of the first kidney transplantation on survival in children initiating renal replacement therapy.

Nephrol Dial Transplant. 2012; 27(3):1256-64.

116: Wühl E, van Stralen KJ, Verrina E, **Bjerre A**, Wanner C, Heaf JG, Zurriaga O, Hoitsma A, Niaudet P, Palsson R, Ravani P, Jager KJ, Schaefer F. Timing and outcome of renal replacement therapy in patients with congenital malformations of the kidney and urinary tract.

Clin J Am Soc Nephrol. 2013;1: 67-74.

115: Osthus TB, von der Lippe N, Ribu L, Rustøen T, Leivestad T, Dammen T, Os I. Health-related quality of life and all-cause mortality in patients with diabetes on dialysis.

BMC Nephrol. 2012;13(1):78.

114 Skauby MH, Øyen O, Hartman A, Leivestad T, Wadström J. Kidney transplantation with and without simultaneous bilateral native nephrectomy in patients with polycystic kidney disease: a comparative retrospective study.

Transplantation. 2012;94(4):383-8.

113: Osthus TB, Preljevic VT, Sandvik L, Leivestad T, Nordhus IH, Dammen T, Os I. Mortality and health-related quality of life in prevalent dialysis patients: Comparison between 12-items and 36-items short-form health survey.

Health Qual Life Outcomes. 2012;10:46.

- 112: Ocak G, van Stralen KJ, Rosendaal FR, Verduijn M, Ravani P, Palsson R, Leivestad T, Hoitsma AJ, Ferrer-Alamar M, Finne P, De Meester J, Wanner C, Dekker FW, Jager KJ. Mortality due to pulmonary embolism, myocardial infarction, and stroke among incident dialysis patients.
J Thromb Haemost. 2012;10(12):2484-2493.
- 111: Harambat J, van Stralen KJ, Espinosa L, Groothoff JW, Hulton SA, Cerkauskiene R, Schaefer F, Verrina E, Jager KJ, Cochat P; European Society for Pediatric Nephrology/European Renal Association-European Dialysis and Transplant Association (ESPN/ERA-EDTA) Registry. (among collaborators: Leivestad T). Characteristics and outcomes of children with primary oxalosis requiring renal replacement therapy.
Clin J Am Soc Nephrol. 2012;7(3):458-65..
- 110: Valderhaug TG, Hjelmessaeth J, Jenssen T, Roislien J, Leivestad T, Hartmann A. Early posttransplantation hyperglycemia in kidney transplant recipients is associated with overall long-term graft losses.
Transplantation 2012; 94(7): 714-20.
- 109: Sandvik LF, Vogelsang P, Leivestad T, Jonsson R, Appel S. Quantification of Plasmacytoid Dendritic Cells and Type 1 Myeloid Dendritic Cells in Peripheral Blood of Renal Transplant Recipients With and Without Squamous Cell Carcinoma.
Acta Derm Venereol. 2012;92(6):623-4
- 108: Mjøen G, **Reisæter A**, Hallan S, Line PD, Hartmann A, Midtvedt K, Foss A, Dahle DO, Holdaas H. Overall and cardiovascular mortality in Norwegian kidney donors compared to the background population.
Nephrol Dial Transplant 2012;27(1):443-7.
- 107: Stel VS, Kramar R, Leivestad T, Hoitsma AJ, Metcalfe W, Smits JM, Ravani P, Jager KJ. Time trend in access to the waiting list and renal transplantation: a comparison of four European countries
Nephrol Dial Transplant 2012; 27: 3621-31.
- 106: Reisæter AV, Foss A, Hartmann A, Leivestad T, Midtvedt K. The Kidney Transplantation Program in Norway since 2000
In: Terasaki PI, Cecka JM (eds). Clinical Transplants 2011. Terasaki Foundation Laboratory, Los Angeles; pp. 111-118.
- 105: Bjørneklett R, Vikse BE, Bostad L, Leivestad T, Iversen BM. Long term risk of ESDR in IgAN; validation of Japanese prognostic model in a Norwegian cohort.
Nephrol Dial Transplant 2012; 27 (4): 1485-91.
- 104: Bleskestad IH, Bergrem H, Leivestad T, Gøransson LG. Intact parathyroid hormone levels in renal transplant patients with normal transplant function.
Clin Transplant. 2011;25: E566-70..

- 103: Carrero JJ, de Jager DJ, Verduijn M, Ravani P, De Meester J, Heaf JG, Finne P, Hoitsma AJ, Pascual J, Jarraya F, **Reisaeter AV**, Collart F, Dekker FW, Jager KJ. Cardiovascular and noncardiovascular mortality among men and women starting dialysis. **Clin J Am Soc Nephrol.** 2011; 6: 1722-1730.
- 102: Heldal K, Hartmann A, Leivestad T, Lien B, Foss AE, Midtvedt K. Nyretransplantasjon er et alternativ for pasienter over 70 år. **Tidsskr Nor Legeforen** 2011; 131: 2004-07.
- 101: Luijtgarden MWMvd, Noordzij M, Stel VS, Ravani P, Jarraya F, Collart F, Schön S, Leivestad T, Puttinger H, Wanner C, Jager KJ. Effects of comorbid and demographic factors on dialysis modality choice and related patient survival in Europe **Nephrol Dial Transplant** 2011; 26: 2940–47.
- 100: Mjøen G, Stavem K, Westlie L, Midtvedt K, **Fauchald P**, Norby G, Holdaas H. Quality of life in kidney donors. **Am J Transplant.** 2011; 11(6): 1315-19.
- 99: Myhre HA, Dorenberg DH, Kristiansen KI, Rollag H, Leivestad T, Åsberg A, Hartmann A. Incidence and outcome of ganciclovir-resistant cytomegalovirus infections in 1244 kidney transplant recipients. **Transplantation** 2011; 92(2):, 217- 223.
- 98: Norby GE, Leivestad T, Mjøen G, Hartmann A, Midtvedt K, Gran JT, Holdaas H. Premature cardiovascular disease in patients with systemic lupus erythematosus influences survival after renal transplantation. **Arthritis Rheum.** 2011;63(3):733-37.
- 97: Bjørneklett R, Vikse BE, Smerud HK, Bostad L, Leivestad T, Hartmann A, Iversen BM. Pre-transplant course and risk of kidney transplant failure in IgA nephropathy patients. **Clin Transplant** 2011; 25: E356-E365.
- 96: Valderhaug TG, Hjelmæsæth J, Hartmann A, Røislien J, Bergrem HA, Leivestad T, Line PD, Jenssen T. The association of early post-transplant glucose levels with long-term mortality. **Diabetologia** 2011; 54: 1341-49.
- 95: Heldal K, Hartmann A, Leivestad T, Foss A, Midtvedt K. Risk variables associated with the outcome of kidney recipients >70 years of age in the new millennium. **Nephrol Dial Transplant** 2011; 26: 2706-11.
- 94: Aasebø W, Midtvedt K, Valderhaug TG, Leivestad T, Hartmann A, Reisaeter AV, Jenssen T, Holdaas H. Impaired glucose homeostasis in renal transplant recipients receiving basiliximab. **Nephrol Dial Transplant** 2010; 25: 1289-1293

93: Heldal K, Hartmann A, Grootendorst DC, Jager DJ de, Leivestad T, Foss A, Midtvedt K. Benefit of kidney transplantation beyond 70 years of age.

Nephrol Dial Transplant 2010; 25: 1680-1687.

92: Vikse BE, Hallan S, Bostad L, Leivestad T, Iversen BM. Previous preeclampsia and risk for progression of biopsy-verified kidney disease to end-stage renal disease.

Nephrol Dial Transplant 2010; 25: 3289-3296.

91: Sandvik MK, Iversen BM, Irgens LM, Skjaerven R, Leivestad T, Søfteland E, Vikse BE. Are adverse pregnancy outcomes risk factors for development of end-stage renal disease in women with diabetes?

Nephrol Dial Transplant 2010; 25: 3600-3607.

90: Bergrem HA, Gretland Valderhaug T, Hartmann A, Hjelmesæth J, Leivestad T, Bergrem H, Jenssen T. Undiagnosed Diabetes in Kidney Transplant Candidates: A Case-Finding Strategy.

Clin J Am Soc Nephrol 2010 5(4): 616-22

89: Gude E, Andreassen AK, Arora S, Gullestad L, Grov I, Hartmann A, Leivestad T, Fiane AE, Geiran OR, Vardal M, Simonsen S. Acute renal failure early after heart transplantation: risk factors and clinical consequences.

Clin Transplant 2010; 24 (6): E207-E213

88: Norby GE, Strøm EH, Midtvedt K, Hartmann A, Gilboe IM, Leivestad T, Stenstrøm J, Holdaas H. Recurrent lupus nephritis after kidney transplantation: a surveillance biopsy study.

Ann Rheum Dis. 2010;69: 1484-1487.

87: Couchoud C, Kooman J, Finne P, Leivestad T, Stojceva-Taneva O, Ponikvar JB, Collart F, Kramar R, de Francisco A, Kitty J. Jager KJ, on behalf of the QUEST working group on dialysis adequacy. From registry data collection to international comparisons: examples of haemodialysis duration and frequency

Nephrol Dial Transplant 2009; 24: 217-224

86: Couchoud C, Jager KJ, Tomson C, Cabanne JF, Collart F, Finne P, de Francisco A, Frimat L, Garneata L, Leivestad T, Lemaitre V, Limido A, Ots M, Resic H, Stojceva-Taneva O, Kooman J, on behalf of the QUEST working group on dialysis adequacy. Assessment of urea removal in haemodialysis and the impact of the European best practice guidelines.

Nephrol Dial Transplant 2009; 24: 1267-1274

85: Heldal K, Hartmann A, Leivestad T, Svendsen MV, Foss A, Lien B, Midtvedt K. Clinical outcomes in elderly kidney transplant recipients are related to acute rejection episodes rather than pretransplant comorbidity.

Transplantation 2009; 87: 1045-1051

- 84: Kramer A, Stel V, Zoccali C, Heaf J, Ansell D, Gronhagen-Riska C, Leivestad T, Simpson K, Palsson R, Postorino M, Jager K. An update on renal replacement therapy in Europe: ERA-EDTA Registry data from 1997 to 2006
Nephrol Dial Transplant 2009; 24: 3557-3566
- 83: Foss A, Heldal K, Scott H, Foss S, Leivestad T, Jørgensen PF, Scholz T, Midtvedt K. Kidneys from deceased donors more than 75 years perform acceptably after transplantation.
Transplantation 2009; 87: 1437-1441.
- 82: Witczak BJ, Leivestad T, Line PD, Holdaas H, Reisaeter AV, Jenssen TG, Midtvedt K, Bitter J, Hartmann A. Experience from an active preemptive kidney transplantation program--809 cases revisited.
Transplantation 2009; 88: 672-677.
- 81: Vikse BE, Irgens LM, Leivestad T, Hallan S, Iversen BM. Low birth weight increases risk for end-stage renal disease.
J Am Soc Nephrol 2008; 19: 151-157
- 80: Heldal K, Leivestad T, Hartmann A, Svendsen MV, Lien BH, Midtvedt K. Kidney transplantation in the elderly – the Norwegian experience.
Nephrol Dial Transplant 2008; 23: 1026-1031
- 79: Tangeraas T, Bjerre A, Lien B, Kyte A, Monn E, Cvancarova M, Leivestad T, Reisaeter AV. Long-term outcome of pediatric renal transplantation: The Norwegian experience in three eras 1970-2006.
Pediatr Transplantation 2008; 12: 762-768
- 78: Vikse BE, Irgens LM, Leivestad T, Skjærven R, Iversen BM. Preeclampsia and the risk of end-stage renal disease.
N Engl J Med 2008; 359: 800-809
- 77: van Manen JG, van Dijk PCW, Stel VS, Dekker FW, Clèries M, Conte F, Feest TG, Kramar R, Leivestad T, Briggs JD, Stengel B, Jager KJ. Confounding effect of co-morbidity in survival studies in patients on renal replacement therapy.
Nephrol Dial Transplant. 2007; 22: 187-195.
- 76: Øien CM, Reisaeter AV, Leivestad T, Dekker FW, Line PD, Os I. Living donor kidney transplantation: The effects of donor age and gender on short- and long-term outcomes.
Transplantation 2007; 83: 600-606.
- 75: Valderhaug TG, Hjelmessaeth J, Rollag H, Leivestad T, Roislien J, Jenssen T, Hartmann A. Reduced Incidence of New-Onset Posttransplantation Diabetes Mellitus During the Last Decade.
Transplantation 2007; 84: 1125-1130.

74: Hjelvesæth J, Hartmann A, Leivestad T, Holdaas H, Sagedal S, Olstad M, Jenssen T. The impact of early-diagnosed new-onset post-transplantation diabetes mellitus on survival and major cardiac events.

Kidney Int 2006; 69: 588-595.

73: Leivestad T. Behandling av kronisk nyresvikt i Norge – utvikling gjennom de siste 25 år.

LNT-Nytt 2006; 2: 26-28.

72: Hjelvesæth J, Ueland T, Flyvbjerg A, Bollerslev J, Leivestad T, Jenssen T, Krarup Hansen T, Thiel S, Sagedal S, Røislien J, Hartmann A. Early Posttransplant Serum Osteoprotegerin Levels Predict Long-Term (8-Year) Patient Survival and Cardiovascular Death in Renal Transplant Patients.

J. Am. Soc. Nephrol. 2006;17:1746-1754.

71: Yoshino M, Kuhlmann MK, Kotanko P, Greenwood RN, Pisoni RL, Port FK, Jager KJ, Homel P, Augustijn H, de Charro FT, Collart F, Ereik E, Finne P, Garcia-Garcia G, Grönhagen-Riska C, Ioannidis GA, Ivis F, Leivestad T, Løkkegaard F, Lopot F, Jin D-C, Kramar R, Nakao T, Nandakumar M, Ramirez S, van der Sande FM, Schön S, Simpson K, Walker RG, Zaluska W, Levin NW. International Differences in Dialysis Mortality Reflect Background General Population Atherosclerotic Cardiovascular Mortality

J Am Soc Nephrol 2006;17: 3510-3519.

70: Stewart JH, McCredie MRE, Williams SM, Jager KJ, Trpeski L, McDonald SP, Fenton SS, van Dijk PCW, Finne P, Schön S, Leivestad T, Løkkegaard H, Billiow J-M, Kramar R, Magaz A, Vela E, Garcia-Blasco MJ, Ioannidis GA, Lim YN. The enigma of hypertensive ESRD: Observations on incidence and trends in 18 European, Canadian, and Asian-Pacific populations, 1998 to 2002.

Am J Kidney Dis 2006; 48: 183-191

69: Flesland Ø, Leivestad T, Solheim BG. Survival of renal allografts from living donors and the importance of being the mother of the organ donor.

Transfusion and Apheresis Science 2005; 32: 13-15.

68: Øien CM, Reisæter AV, Leivestad T, Pfeffer P, Fauchald P, Os I. Gender imbalance among donors in living kidney transplantation: the Norwegian experience.

Nephrol Dial Transplant. 2005; 20: 783-9.

67: Stel V.S., P.C.W. van Dijk, J.G. van Manen, F.W. Dekker, F. Conte, D. Ansell, R. Kramar, T. Leivestad, E. Vela, J. D. Briggs, K.J. Jager. Prevalence of co-morbidity in different European RRT populations and its effect on access to renal transplantation.

Nephrol Dial Transplant. 2005; 20: 2803-11.

66: Foss A, Tuvin D, Leivestad T, Øyen O, Bentsdal Ø. Should kidneys from older cadaveric donors be age-matched to the recipient?

Transplant Proc 2005; 37: 3280-2.

- 65: Sagedal S, Hartmann A, Nordal KP, Foss A, Degré M, Leivestad T, Osnes K, Fauchald P, Rollag H. Impact of early cytomegalovirus infection and disease on long-term recipient and kidney graft survival.
Kidney Int 2004;66:329-337
- 64: E. Thorsby, P. Pfeffer, T. Leivestad. Role of HLA molecules in the induction of alloimmune responses: Clinical significance in the cyclosporine era.
Transplant Proc 2004; 36(Suppl 2S):16-21.
- 63: D. Albrechtsen, T. Leivestad, P. Fauchald, P. Pfeffer on behalf of the Oslo Kidney Transplant Group. Experience with cyclosporine in 1519 kidney transplantations from living donors in a national transplant programme 1983-2002.
Transplant Proc 2004; 36(Suppl 2S):89-93.
- 62: Midtvedt K, Fauchald P, Lien B, Hartmann A, Albrechtsen D, Bjerkely B.L, Leivestad T, Brekke I.B. Individualized T cell monitored administration of ATG versus OKT3 in steroid-resistant kidney graft rejection.
Clin Transplant 2003; 17: 69-74.
- 61: Westlie L, Leivestad T, Holdaas H, Lien B, Meyer K, Fauchald P. Hvordan går det med dem som donerer en nyre til transplantasjon?
Tidsskr Nor Lægeforen 2003; 123: 1060-1062.
- 60: Westlie L, Leivestad T, Holdaas H, Lien B, Hartmann A, Fauchald P. Er dagens praksis ved bruk av levende giver ved nyretransplantasjon akseptabel?
Tidsskr Nor Lægeforen 2003; 123: 1063-1065.
- 59: Witczak B, Hartmann A, Leivestad T, Øyen O, Svennevig J. Cardiovascular surgery in renal failure patients with or without subsequent renal transplantation.
Transplant Proc 2003; 35: 798-800.
- 58: Jakobsen A, Holdaas H, Leivestad T. Ethics and safety of living kidney donation.
Transplant Proc 2003; 35: 1177-1178.
- 57: Westlie L, Leivestad T, Holdaas H, Lien B, Meyer K, Fauchald P. Report from the Norwegian National Hospitals Living Donor Registry: one-year data, January 1, 2002.
Transplant Proc 2003;35:777-778.
- 56: Midtvedt K, Fauchald P, Bergan S, Høieggen A, Hallan S, Svarstad E, Bergrem H, Eriksen BO, Pfeffer PF, Dalen I, Leivestad T. C₂ monitoring in maintenance renal transplant recipients: Is it worthwhile?
Transplantation 2003;76:1236-1238.
- 55: Sagedal S, Nordal KP, Hartmann A, Sund S, Scott H, Degré M, Foss A, Leivestad T, Fauchald P, Rollag H. The impact of cytomegalovirus infection and disease on rejection episodes in renal allograft recipients.
Am J Transpl 2002; 2: 850-856.

- 54: Bergrem H, Leivestad T. Diabetic nephropathy and end-stage renal failure: The Norwegian story.
Adv Ren Replace Ther 2001; 8: 4-12.
- 53: Fauchald P, Leivestad T. Nyretransplantasjon ved diabetisk nyresvikt.
Diabetes for helsepersonell 2001; 1: 4-6.
- 52: Dijk PCWv, Jager KJ, Charro Fd, Collart F, Cornet R, Dekker FW, Grönhagen-Riska C, Kramar R, Leivestad T, Simpson K, Briggs JD. Renal replacement therapy in Europe: the results of a collaborative effort by the ERA-EDTA registry and six national or regional registries.
Nephrol Dial Transplant 2001; 16: 1120-1129.
- 51: Leivestad T. Norsk Nefrologiregister fra 1980 til 2000.
LNT-Nytt 2001; 5: 10-11.
- 50: Katre S, Leivestad T, Fauchald P. Aktiv uremibehandling ved autosomal dominant polycystisk nyresykdom..
Tidsskr Nor Lægeforen 2000; 120: 1015-1019.
- 49: Gjersvik P, Hansen S, Møller B, Leivestad T, Geiran O, Simonsen S, Pfeffer P, Fauchald P. Are heart transplant recipients more likely to develop skin cancer than kidney transplant recipients?
Transpl Int 2000; 13 (suppl 1): 380-381
- 48: Sagedal S, Nordal KP, Hartmann A, Degré M, Holter E, Foss A, Osnes K, Leivestad T, Fauchald P, Rollag H. A prospective study of the natural course of cytomegalovirus infection and disease in renal allograft recipients.
Transplantation 2000; 70: 1166-1174.
- 47: Hartmann A, Leivestad T. Behandling av pasienter med kronisk diabetisk nyresvikt.
Diabetes for helsepersonell 2000; 3: 14-17
- 46: Paulsen D, Kløw NE, Rogstad B, Leivestad T, Lien B, Vatne K, Fauchald P. Preservation of renal function by percutaneous transluminal angioplasty in ischemic renal disease.
Nephrol Dial Transplant 1999; 14: 1454-1461
- 45: Jensen P, Hansen S, Møller B, Leivestad T, Pfeffer P, Geiran O, Fauchald P, Simonsen S. Skin cancer in kidney and heart transplant recipients and different long-term immunosuppressive therapy regimens.
J Am Acad Dermatol 1999; 49: 177-186
- 44: Jakobsen A, Leivestad T, Foss A. The use of unrelated living renal donors and the «cross-over» debate.

In: Malacrida R, Martinoli S, Thiel G, Wullschleger R (eds). Donazioni e trapianti d'organo. I trapianti dai vivi (The Living Donors). Edizioni Alice, CH-6949 Comano; pp 53-57, 1999.

43: Bentsdal ØH, Leivestad T, Fauchald P, Albrechtsen D, Pfeffer P, Lien B, Foss A, Øyen O, Hartmann A, Nordal K, Sjødal G, Flatmark A, Thorsby E, Brekke IB. The national kidney transplant program in Norway still results in unchanged waiting lists.

In: Terasaki PI, Cecka JM (eds). Clinical Transplants 1998. UCLA Tissue Typing Laboratory, Los Angeles; pp. 221-228, 1999.

42: Leivestad T, Reisæter AV, Brekke IB, Vartdal F, Thorsby E. The role of HLA matching in renal transplantation: experience from one center.

Rev Immunogenetics 1999;1: 343-350.

41: Jensen P, Hansen S, Møller B, Leivestad T, Pfeffer P, Fauchald P. Are renal transplant recipients on CsA-based immunosuppressive regimens more likely to develop skin cancer than those on azathioprine and prednisolone?

Transplant Proc 1999; 31: 1120

40: Leivestad T. Norsk Nefrologiregister. 25 år med datainnsamling.

In: Westlie L (ed). Norsk nyremedisin. Et moderne eventyr. Norsk nyremedisinsk forening, Fredrikstad; pp. 104-111, 1999.

39: Reisæter AV, Leivestad T, Vartdal F, Spurkland A, Fauchald P, Brekke IB, Thorsby E. A strong impact of matching for a limited number of HLA-DR antigens on graft survival and rejection episodes. A single center study of first cadaveric kidneys to non-sensitized recipients.

Transplantation 1998; 66: 523-528

38: Foss A, Leivestad T, Brekke IB, Fauchald P, Bentsdal Ø, Lien B, Pfeffer P, Sjødal G, Albrechtsen D, Sjøreide O, Flatmark A. Unrelated living donors in 141 kidney transplantations. A one-center study.

Transplantation 1998; 66: 49-52

37: Bergan S, Rugstad HE, Bentsdal Ø, Sjødal G, Hartmann A, Leivestad T, Stokke O. Monitored high-dose azathioprine treatment reduces acute rejection episodes after renal transplantation.

Transplantation 1998; 66: 334-339

36: Reisæter AV, Leivestad T, Fauchald P, Brekke I, Thorsby E. Influence of matching for HLA-DR in first cadaveric renal transplantation in nonsensitized recipients.

Transplant Proc 1997; 29: 3099-3100.

35: Pfeffer PF, Leivestad T, Albrechtsen D, Fauchald P, Brekke IB. Anamnestic cancer: How long should the cancer-free interval be before renal transplantation?

Transplant Proc 1997; 29: 3163.

- 34: Hjelvesæth J, Hartmann A, Kofstad J, Stenstrøm J, Leivestad T, Egeland T, Fauchald P. Glucose intolerance following renal transplantation depends upon prednisolone dose and recipient age.
Transplantation 1997; 64: 979-983
- 33: Midtvedt K, Tafjord AB, Hartmann A, Nordal KP, Holdaas H, Sødal G, Leivestad T, Fauchald P. Half dose of OKT3 is efficient in treatment of steroid resistant renal allograft rejection.
Transplantation 1996; 62: 38-42.
- 32: Brekke IB, Sødal G, Holdaas H, Fauchald P, Jervell J. Simultaneous pancreas and kidney transplantation. **In:** Mogensen CE (ed.): The kidney and hypertension in diabetes mellitus. 3. edition. Martinus Nijhoff Publishing, Boston; pp 513-520, 1996.
- 31: Jakobsen A, Albrechtsen D, Leivestad T. Renal transplantation - The Norwegian model.
Annals of Transplantation 1996; 1: 32-35.
- 30: Leivestad T, Spurkland A, Knutsen I, Bratlie A, Vartdal F, Pfeffer P, Sødal G, Fauchald P, Thorsby E. Genomic HLA-DRB1 matching further improves clinical course after renal transplantation.
Transplant Proc 1995; 27: 678-679.
- 29: Albrechtsen D, Leivestad T, Sødal G, Bentsdal Ø, Berg KJ, Brekke I, Fauchald P, Flatmark A, Jakobsen A, Lien B, Nordal K, Pfeffer P, Thorsby E, Søreide O. Kidney transplantation in patients older than 70 years of age.
Transplant Proc 1995; 27: 986-988
- 28: Reisaether AV, Leivestad T, Holdaas H, Hartmann A, Sødal G, Albrechtsen D, Flatmark A, Fauchald P. Pretransplant plasma exchange or immunoadsorption facilitates renal transplantation in immunized patients.
Transplantation 1995; 60: 242-248.
- 27: Reisaether AV, Fauchald P, Leivestad T, Holdaas H, Hartmann A, Pfeffer P, Sødal G. Plasma exchange in highly sensitized patients as induction therapy after renal transplantation.
Transplant Proc 1994; 26: 1758.
- 26: Fauchald P, Leivestad T, Rollag H, Albrechtsen D, Sødal G. The influence of cytomegalovirus antibody status on graft survival in renal transplantation.
Transplant Proc 1994; 26: 1725
- 25: Leivestad T, Spurkland A, Bratlie A, Pfeffer P, Fauchald P, Sødal G, Thorsby E. Does genomic HLA-DR matching further enhance the effects of serological DR matching in clinical renal transplantation?
Transplant Proc 1994; 26: 1748-1749.

- 24: Haugen G, Fauchald P, Sødal G, Leivestad T, Moe N. Pregnancy outcome in renal allograft recipients in Norway: The importance of immunosuppressive drug regimen and health status before pregnancy.
Acta Obstet Gynecol Scand 1994; 73: 541-546.
- 23: Leivestad T, Thorsby E. Transplantationer. Betydningen av god HLA-forlikelighet. (The importance of HLA compatibility in organ transplantation).
Nord Med 1994; 109: 188-190.
- 22: Leivestad T, Sødal G, Bratlie A, Albrechtsen D, Fauchald P, Pfeffer P, Vartdal F, Thorsby E. Role of HLA matching in cadaveric renal transplantation - influence of improved serological HLA-DR typing.
Transplant Proc 1993; 25: 220-221.
- 21: Albrechtsen D, Leivestad T, Fauchald P, Flatmark A, Sødal G, Thorsby E. Results of the national kidney transplantation program in Norway.
In: Terasaki PI, Cecka JM (eds). Clinical Transplants 1992. UCLA Tissue Typing Laboratory, Los Angeles; pp. 207-213 1993.
- 20: Pfeffer PF, Ohlman S, Jakobsen A, Fauchald P, Leivestad T, Tydén G, Flatmark A. A Scandinavian two-center study of BMA 031 in steroid-resistant rejection of renal grafts.
Transplantation 1993; 56: 304-307.
- 19: Westlie L, Fauchald P, Talseth T, Jakobsen A, Flatmark A. Quality of life in Norwegian kidney donors.
Nephrol Dial Transplant 1993; 8: 1146-1150
- 18: Hartmann A, Holdaas H, Fauchald P, Nordal KP, Berg KJ, Talseth T, Leivestad T, Brekke IB, Flatmark A. Fifteen years experience with renal transplantation in systemic amyloidosis.
Transplant Int 1992; 5: 15-18.
- 17: Gorlén T, Abdelnoor M, Enger E, Halvorsen S, Leivestad T, Malm OJ, Aarseth HP. Long term morbidity and mortality after kidney transplantation.
Scand J Urol Nephrol 1992; 26: 397-401.
- 16: Pfeffer PF, Jakobsen A, Albrechtsen D, Sødal G, Brekke I, Bentdal Ø, Leivestad T, Fauchald P, Flatmark A. BMA 031 effectively reverses steroid-resistant rejections in renal transplants.
Transplant Proc 1991; 23: 1099-1100.
- 15: Fauchald P, Sødal G, Albrechtsen D, Leivestad T, Berg KJ, Flatmark A. The use of elderly living donors in renal transplantation.
Transplant Int 1991; 4: 51-53.
- 14: Jakobsen A, Albrechtsen D, Fauchald P, Leivestad T, Sødal G, Flatmark A. Allowing relatives to bridge the gap: The Norwegian experience.

In: Land W, Dossetor JB (eds). Organ replacement therapy: Ethics, justice and commerce. Springer-Verlag Berlin Heidelberg pp.48-49 1991.

13: Fauchald P, Berg KJ, Brodwall EK, Talseth T, Flatmark A, Leivestad T, Halvorsen S. Behandling av kronisk nyresvikt med dialyse og transplantasjon. Utvikling, behov og organisering i Norge. (Renal replacement therapy in Norway - development, requirement and organization)

Tidsskr Nor Lægeforen 1990; 110: 332-334.

12: Leivestad T, Albrechtsen D, Bratlie A, Jakobsen A, Pfeffer P, Sødal G, Vartdal F, Flatmark A, Thorsby E. The role of HLA compatibility in renal transplantation from living donors. An analysis of 379 grafts.

Transplant Proc 1990; 22: 153.

11: Fauchald P, Leivestad T, Albrechtsen D, Willassen Y, Jakobsen A, Flatmark A. Plasma exchange and immunadsorption prior to renal transplantation in allosensitized patients.

Transplant Proc 1990; 22: 149-150.

10: Albrechtsen D, Berg KJ, Brekke I, Fauchald P, Jakobsen A, Sødal G, Talseth T, Leivestad T, Flatmark A. Renal replacement therapy in the cyclosporine era: Results of a national transplantation program.

Transplant Proc 1990; 22: 155-156.

9: Albrechtsen D, Flatmark A, Leivestad T, Brynger H, Frødin L, Groth CG, Lundgren G, Persson N. Efficacy of cyclosporine in renal transplantation from HLA haploidentical living donors: No benefit of transfusion or additional azathioprine.

Transplant Proc 1990; 22: 214-215.

8: Jakobsen A, Albrechtsen D, Leivestad T, Sødal G, Talseth T, Flatmark A. Steroid resistant rejection: The effect of ATG on renal allograft survival.

Transplant Proc 1990; 22: 225.

7: Albrechtsen D, Sødal G, Jakobsen A, Brekke I, Bentsdal Ø, Berg KJ, Fauchald P, Pfeffer P, Talseth T, Leivestad T, Flatmark A. Kidney transplantation from a spouse: An alternative to years of dialysis waiting for a graft that may never turn up?

Transplant Proc 1990; 22: 1435.

6: Flesland Ø, Solheim BG, Gaustad P, Mellbye O, Albrechtsen D, Talseth T, Leivestad T. Antibody production by donor lymphocytes in transplant patients.

Transplantation 1989; 48: 883-885.

5: Fauchald P, Albrechtsen D, Leivestad T, Pfeffer P, Talseth T, Flatmark A. Renal replacement therapy in patients over 60 years of age.

Transplant Proc 1988; 20: 432-433.

4: Albrechtsen D, Fauchald P, Leivestad T, Talseth T, Flatmark A. Renal replacement therapy in elderly patients.

Transplant Proc 1988; 20: 367-369.

3: Fauchald P, Albrechtsen D, Leivestad T, Berg KJ, Talseth T, Flatmark A. Renal replacement therapy in elderly patients.

Transplant Int 1988; 1: 131-134.

2: Nordal KP, Dahl E, Albrechtsen D, Halse J, Leivestad T, Tretli S, Flatmark A. Aluminium accumulation and immunosuppressive effect in recipients of kidney transplants.

Brit Med J 1988; 297: 1581-1582.

1: Fauchald P, Leivestad T, Bratlie A, Albrechtsen D, Talseth T, Flatmark A. Plasma exchange and immunosuppressive therapy before renal transplantation in allosensitized patients.

Transplant Proc 1987; 19: 3748-3749.